Market revenue in 2024 | USD 4,372.4 million |
Market revenue in 2030 | USD 6,961.6 million |
Growth rate | 8.3% (CAGR from 2025 to 2030) |
Largest segment | Continuous blood glucose monitoring system |
Fastest growing segment | Smart insulin pens |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Smart glucose meter, Continuous blood glucose monitoring system, Smart insulin pens, Smart Insulin Pumps/Closed Loop Systems, Apps |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, Roche Holding AG ADR, Bayer AG, Sanofi SA, DexCom Inc, Insulet Corp, PHC Holdings Corp, B. Braun Medical, Brigade High Income Founders |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to digital diabetes management market will help companies and investors design strategic landscapes.
Continuous blood glucose monitoring system was the largest segment with a revenue share of 43.13% in 2024. Horizon Databook has segmented the U.S. digital diabetes management market based on smart glucose meter, continuous blood glucose monitoring system, smart insulin pens, smart insulin pumps/closed loop systems, apps covering the revenue growth of each sub-segment from 2018 to 2030.
In North America, the U.S. dominated the market owing to a high prevalence of diabetes and the availability of favorable reimbursement policies. High per capita income and increasing healthcare expenditure are among the key factors expected to drive the market.
Furthermore, the adoption of smart devices, coupled with technological advancements such as AI and data analytics, is expected to propel the market. The market is expected to experience the launch of several products in the near future.
For Instance, In February 2018, Novo Nordisk announced the launch of its smart insulin pen, which was expected to be launched in the U.S., depending on FDA approval. In December 2017, Companion Medical launched Inpen, its first smart insulin pen system, in the U.S. It is the only FDA-approved solution that combines an insulin injector pen with an app.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. digital diabetes management market, including forecasts for subscribers. This country databook contains high-level insights into U.S. digital diabetes management market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account